These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 11479851

  • 1. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
    Soffer SZ, Moore JT, Kim E, Huang J, Yokoi A, Manley C, O'Toole K, Stolar C, Middlesworth W, Yamashiro DJ, Kandel JJ.
    J Pediatr Surg; 2001 Aug; 36(8):1177-81. PubMed ID: 11479851
    [Abstract] [Full Text] [Related]

  • 2. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor.
    Soffer SZ, Kim E, Moore JT, Huang J, Yokoi A, Manley C, O'Toole K, Middlesworth W, Stolar C, Yamashiro D, Kandel J.
    J Pediatr Surg; 2001 Dec; 36(12):1781-4. PubMed ID: 11733906
    [Abstract] [Full Text] [Related]

  • 3. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW, Hopkins B, Frischer J, Novikov A, Huang J, Kadenhe A, New T, Yokoi A, Yamashiro DJ, Kandel JJ, Middlesworth W.
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [Abstract] [Full Text] [Related]

  • 4. All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor.
    Kim E, Moore J, Huang J, Soffer S, Manley CA, O'Toole K, Middlesworth W, Stolar CJ, Kandel JJ, Yamashiro DJ.
    J Pediatr Surg; 2001 Feb; 36(2):287-90. PubMed ID: 11172417
    [Abstract] [Full Text] [Related]

  • 5. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
    Frischer JS, Huang J, Serur A, Kadenhe-Chiweshe A, McCrudden KW, O'Toole K, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ.
    Int J Oncol; 2004 Sep; 25(3):549-53. PubMed ID: 15289855
    [Abstract] [Full Text] [Related]

  • 6. Suppression of primary tumor growth in a mouse model of human neuroblastoma.
    Rowe DH, Huang J, Li J, Manley C, O'Toole KM, Stolar CJ, Yamashiro DJ, Kandel JJ.
    J Pediatr Surg; 2000 Jun; 35(6):977-81. PubMed ID: 10873048
    [Abstract] [Full Text] [Related]

  • 7. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G.
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [Abstract] [Full Text] [Related]

  • 8. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

  • 9. Distinct response of experimental neuroblastoma to combination antiangiogenic strategies.
    Kim ES, Soffer SZ, Huang J, McCrudden KW, Yokoi A, Manley CA, Middlesworth W, Kandel JJ, Yamashiro DJ.
    J Pediatr Surg; 2002 Mar; 37(3):518-22. PubMed ID: 11877680
    [Abstract] [Full Text] [Related]

  • 10. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y.
    Cancer Res; 2000 Oct 01; 60(19):5565-70. PubMed ID: 11034104
    [Abstract] [Full Text] [Related]

  • 11. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
    Borgström P, Gold DP, Hillan KJ, Ferrara N.
    Anticancer Res; 1999 Oct 01; 19(5B):4203-14. PubMed ID: 10628376
    [Abstract] [Full Text] [Related]

  • 12. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model.
    Abramson LP, Stellmach V, Doll JA, Cornwell M, Arensman RM, Crawford SE.
    J Pediatr Surg; 2003 Mar 01; 38(3):336-42; discussion 336-42. PubMed ID: 12632345
    [Abstract] [Full Text] [Related]

  • 13. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
    Ghosh S, Maity P.
    Int Immunopharmacol; 2006 Oct 01; 6(10):1550-9. PubMed ID: 16919827
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
    Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP.
    Clin Cancer Res; 2002 Apr 01; 8(4):1258-70. PubMed ID: 11948141
    [Abstract] [Full Text] [Related]

  • 15. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE.
    Cancer Res; 2002 Apr 01; 62(7):2034-42. PubMed ID: 11929822
    [Abstract] [Full Text] [Related]

  • 16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 17. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors.
    Huang J, Moore J, Soffer S, Kim E, Rowe D, Manley CA, O'Toole K, Middlesworth W, Stolar C, Yamashiro D, Kandel J.
    J Pediatr Surg; 2001 Feb 15; 36(2):357-61. PubMed ID: 11172434
    [Abstract] [Full Text] [Related]

  • 18. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
    Dagnaes-Hansen F, Rasmussen LM, Tilton R, Denner L, Flyvbjerg A.
    Anticancer Res; 2003 Feb 15; 23(2B):1625-30. PubMed ID: 12820432
    [Abstract] [Full Text] [Related]

  • 19. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
    Bauer TW, Fan F, Liu W, Camp ER, Yang A, Somcio RJ, Bucana CD, Singh R, Ellis LM.
    Ann Surg Oncol; 2007 Oct 15; 14(10):2838-46. PubMed ID: 17653802
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1558-70. PubMed ID: 17077358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.